[go: up one dir, main page]

SG11202012435UA - Compositions and methods for treating cancer - Google Patents

Compositions and methods for treating cancer

Info

Publication number
SG11202012435UA
SG11202012435UA SG11202012435UA SG11202012435UA SG11202012435UA SG 11202012435U A SG11202012435U A SG 11202012435UA SG 11202012435U A SG11202012435U A SG 11202012435UA SG 11202012435U A SG11202012435U A SG 11202012435UA SG 11202012435U A SG11202012435U A SG 11202012435UA
Authority
SG
Singapore
Prior art keywords
compositions
methods
treating cancer
cancer
treating
Prior art date
Application number
SG11202012435UA
Inventor
Stéphanie Chanteux
Laurent Gauthier
Nicolas Gourdin
Carine Paturel
Ivan Perrot
Benjamin Rossi
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Publication of SG11202012435UA publication Critical patent/SG11202012435UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202012435UA 2018-06-18 2019-06-17 Compositions and methods for treating cancer SG11202012435UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862686165P 2018-06-18 2018-06-18
PCT/EP2019/065877 WO2019243252A1 (en) 2018-06-18 2019-06-17 Compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
SG11202012435UA true SG11202012435UA (en) 2021-01-28

Family

ID=67137899

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012435UA SG11202012435UA (en) 2018-06-18 2019-06-17 Compositions and methods for treating cancer

Country Status (17)

Country Link
US (3) US11377503B2 (en)
EP (1) EP3807316B1 (en)
JP (2) JP7500442B2 (en)
KR (1) KR102826033B1 (en)
CN (1) CN112334486B (en)
AR (1) AR115566A1 (en)
AU (1) AU2019289646A1 (en)
BR (1) BR112020024412A8 (en)
CA (1) CA3099893A1 (en)
DK (1) DK3807316T3 (en)
EA (1) EA202092518A1 (en)
ES (1) ES2994131T3 (en)
MX (1) MX2020012107A (en)
PT (1) PT3807316T (en)
SG (1) SG11202012435UA (en)
TW (1) TWI870353B (en)
WO (1) WO2019243252A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032025T2 (en) 2008-01-31 2017-08-28 Inserm - Inst Nat De La Sante Et De La Rech Medicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
WO2018167267A1 (en) 2017-03-16 2018-09-20 Innate Pharma Compositions and methods for treating cancer
US11377503B2 (en) 2018-06-18 2022-07-05 Innate Pharma Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide
AU2020260693A1 (en) * 2019-04-23 2021-10-28 Innate Pharma CD73 blocking antibodies
EP4294846A4 (en) * 2021-02-19 2025-03-12 Janssen Biotech, Inc. MATERIALS AND METHODS FOR TARGETING REGULATORY T CELLS TO IMPROVE IMMUNE SURVEILLANCE
IL315351A (en) 2022-03-03 2024-11-01 Arcus Biosciences Inc Anti-cd39 antibodies and use thereof
AU2023402712A1 (en) 2022-12-01 2025-05-08 Innate Pharma Compositions and methods for neoadjuvant treatment in cancer comprising anti-cd39 antibodies

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
JPS63502716A (en) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー How to enhance glycoprotein stability
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0689601B1 (en) 1993-02-22 2006-10-04 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (en) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition for the production of therapeutic products in vivo.
KR100261941B1 (en) 1994-07-13 2000-07-15 나가야마 오사무 Reconstituted human antibody against human interleukin-8
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
CN1241944C (en) 1995-09-11 2006-02-15 协和发酵工业株式会社 Antibody againts 'alpha'-chain of human interleukin 5 receptor
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JP2001522241A (en) 1997-04-10 2001-11-13 ロイヤル ネザーランズ アカデミー オブ アーツ アンド サイエンシズ Diagnostic methods and reagents
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2003052121A2 (en) 2001-12-17 2003-06-26 Beth Israel Deaconess Medical Center Method of reducing angiogenesis
EP1513554B9 (en) 2002-05-30 2011-11-09 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
US20050037382A1 (en) 2003-04-08 2005-02-17 Robson Simon C. Methods and compositions for treating and preventing autoimmune disorders
WO2006083289A2 (en) 2004-06-04 2006-08-10 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
WO2006113237A2 (en) 2005-04-18 2006-10-26 Metabolex, Inc. Cd39l3 and its role in diabetes
WO2006111986A1 (en) 2005-04-19 2006-10-26 Fondazione Santa Lucia I.R.C.C.S. Method for the detection and the isolation of immunosuppressive regulatory t cells and uses thereof
CA2607147C (en) 2005-05-09 2018-07-17 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
UA99701C2 (en) 2005-07-01 2012-09-25 Медарекс, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY Binds TO LIGAND-1 PROGRAMMED CELL DAMAGE (PD-L1)
EP2641618A3 (en) 2007-07-16 2013-10-23 Genentech, Inc. Humanized anti-CD79B antibodies and immunoconjugates and methods of use
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
HUE032025T2 (en) 2008-01-31 2017-08-28 Inserm - Inst Nat De La Sante Et De La Rech Medicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
BRPI0907718A2 (en) 2008-02-11 2017-06-13 Curetech Ltd method for treating a tumor, method for improving tolerability to at least one chemotherapeutic agent, method for increasing survival of an individual having a tumor, method for reducing or preventing tumor recurrence, use of a humanized monoclonal antibody or fragment and antibody thereof humanized monoclonal or fragment thereof
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
RU2636023C2 (en) 2008-12-09 2017-11-17 Дженентек, Инк. Antibodies to pd-l1 and their application for t-cells function strengthening
KR101790767B1 (en) 2009-11-24 2017-10-26 메디뮨 리미티드 Targeted binding agents against b7-h1
MX2012006243A (en) 2009-11-30 2012-10-15 Janssen Biotech Inc Antibody fc mutants with ablated effector functions.
US8865653B2 (en) 2010-04-22 2014-10-21 Institut Gustave Roussy Method of treatment for immunogenic treatment resistant cancer
AR083847A1 (en) 2010-11-15 2013-03-27 Novartis Ag FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES
EP2654789B1 (en) 2010-12-22 2018-05-30 Orega Biotech Antibodies against human cd39 and use thereof
SMT201700201T1 (en) 2010-12-23 2017-05-08 Janssen Biotech Inc Active protease-resistant antibody fc mutants
WO2012145493A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
DK3424953T3 (en) 2011-06-06 2020-11-02 Novo Nordisk As Terapeutiske antistoffer
KR102049817B1 (en) 2011-08-01 2019-12-02 제넨테크, 인크. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
FR3011240A1 (en) 2013-10-01 2015-04-03 Centre Nat Rech Scient 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF
UA119659C2 (en) 2013-12-12 2019-07-25 Шанхай Хенжуй Фармасьютикал Ко., Лтд. ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION
US10654884B2 (en) 2014-04-25 2020-05-19 Boehringer Ingelheim International Gmbh Purine derivatives as CD73 inhibitors for the treatment of cancer
WO2016131950A1 (en) 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
RU2746804C2 (en) 2014-10-10 2021-04-21 Иннейт Фарма Blockade cd73
EP3215538A4 (en) 2014-11-07 2018-07-04 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
FI3218406T4 (en) 2014-11-10 2024-12-07 Medimmune Ltd BINDING MOLECULES SPECIFIC FOR CD73 AND USES THEREOF
US20160129108A1 (en) 2014-11-11 2016-05-12 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and uses thereof
CA2968357A1 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
EP3380519A1 (en) 2015-11-23 2018-10-03 Innate Pharma Cd39 vascular isoform targeting agents
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
KR20180134837A (en) 2015-12-09 2018-12-19 코버스 파마슈티칼스, 인크. Humanized anti-CD73 antibody
EA038565B1 (en) 2016-01-08 2021-09-15 Аркус Байосайенсиз, Инк. Modulators of ecto-5'-nucleotidase and the use thereof
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
EP3912681A1 (en) 2016-03-14 2021-11-24 Orega Biotech Anti-cd39 antibodies
JP7150712B2 (en) 2016-11-18 2022-10-11 アーカス バイオサイエンシズ インコーポレイティド Inhibitors of CD73-mediated immunosuppression
WO2018167267A1 (en) 2017-03-16 2018-09-20 Innate Pharma Compositions and methods for treating cancer
PE20200717A1 (en) 2017-06-22 2020-07-21 Novartis Ag ANTIBODY MOLECULES THAT BIND AND USES CD73
JP7113071B2 (en) 2017-07-31 2022-08-04 トリシュラ セラピューティクス， インコーポレイテッド Anti-CD39 Antibodies, Compositions Comprising Anti-CD39 Antibodies, and Methods of Using Anti-CD39 Antibodies
JP7274469B2 (en) 2017-10-06 2023-05-16 イナート・ファルマ・ソシエテ・アノニム Restoration of T cell activity by the CD39/CD73 axis
JP7383609B2 (en) 2017-11-15 2023-11-20 イナート・ファルマ・ソシエテ・アノニム Enhancement of the effect of ATP release
US11377503B2 (en) 2018-06-18 2022-07-05 Innate Pharma Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide

Also Published As

Publication number Publication date
KR102826033B1 (en) 2025-06-27
KR20210023983A (en) 2021-03-04
US20230025732A1 (en) 2023-01-26
MX2020012107A (en) 2021-01-29
US20200024357A1 (en) 2020-01-23
BR112020024412A2 (en) 2021-03-23
PT3807316T (en) 2024-07-29
CN112334486B (en) 2025-02-18
US11377503B2 (en) 2022-07-05
AR115566A1 (en) 2021-02-03
CN112334486A (en) 2021-02-05
JP2021528063A (en) 2021-10-21
TW202016142A (en) 2020-05-01
CA3099893A1 (en) 2019-12-26
EA202092518A1 (en) 2021-08-23
EP3807316B1 (en) 2024-05-01
WO2019243252A1 (en) 2019-12-26
AU2019289646A1 (en) 2020-11-26
DK3807316T3 (en) 2024-07-29
EP3807316A1 (en) 2021-04-21
BR112020024412A8 (en) 2023-03-21
US20250236678A1 (en) 2025-07-24
JP2024026170A (en) 2024-02-28
TWI870353B (en) 2025-01-21
JP7500442B2 (en) 2024-06-17
ES2994131T3 (en) 2025-01-17
US12202907B2 (en) 2025-01-21

Similar Documents

Publication Publication Date Title
ZA202006627B (en) Methods and compositions for treating cancer
IL267247B (en) Compositions and methods for treating cancer
IL266053A (en) Compositions and methods for treating ezh2-mediated cancer
IL286350A (en) Compositions and methods for treating cancer
IL264034A (en) Crispr/cas9-based compositions and methods for treating cancer
IL276808A (en) Compositions and methods for cancer treatment
IL288914A (en) Compositions and methods for treating cancer
IL255929A (en) Compositions and methods for treating cancer
ZA202104870B (en) Methods and compositions for treating cancer
IL274837A (en) Methods and compositions for treating cancers
SG11202012435UA (en) Compositions and methods for treating cancer
IL287982A (en) Compositions and methods for treating cancer
EP3638293A4 (en) Methods and compositions for treating cancer
SG11202106295WA (en) Compositions and methods for cancer therapy
SG11202109336UA (en) Methods and compositions for treating cancer
IL255638A (en) Compositions and methods for treating cancer
IL276203A (en) Compositions and methods of treating cancer
IL286153A (en) Methods and compositions for treating cancer
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
EP3714043A4 (en) Compositions and methods for treating cancer
SG11202002123XA (en) Compositions and methods for treating liver cancer
IL272782A (en) Compositions and methods for treating cancer
EP3773585A4 (en) Compositions and methods for treating cancer
SG11202104692VA (en) Compositions and methods for treating cancer
IL285036A (en) Methods and compositions for treating cancer